TKT to Present at JPMorgan's Annual HealthCare Conference
January 04 2005 - 10:02AM
PR Newswire (US)
TKT to Present at JPMorgan's Annual HealthCare Conference
CAMBRIDGE, Mass., Jan. 4 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (NASDAQ:TKTX) today announced that the company will
present at JPMorgan's Annual Healthcare Conference being held in
San Francisco, California, January 10-13, 2005. Michael J. Astrue,
President and Chief Executive Officer will present an overview and
update of TKT's business activities and product pipeline at 4:30
p.m. Pacific Time on Tuesday, January 11, 2005. A live audio
webcast of this presentation will be available at
http://www.tktx.com/ on TKT's Investor Information website under
the Events category. A replay will be available for approximately
30 days after the webcast. About TKT Transkaryotic Therapies, Inc.
is a biopharmaceutical company primarily focused on researching,
developing and commercializing treatments for rare diseases caused
by protein deficiencies. Within this focus, the company markets
Replagal(TM), an enzyme replacement therapy for Fabry disease, and
is developing treatments for Hunter syndrome and Gaucher disease.
In addition to its focus on rare diseases, TKT intends to
commercialize Dynepo(TM), its Gene- Activated(R) erythropoietin
product for anemia related to kidney disease, in the European
Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and
South America. Additional information about TKT is available on the
company's website at http://www.tktx.com/. Gene-Activated(R) is a
registered trademark and Replagal(TM) is a trademark of
Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Sanofi-Aventis SA. Contact: Daniella M. Lutz Corporate
Communications Manager (617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Daniella M. Lutz, Corporate Communications Manager of
Transkaryotic Therapies, Inc., +1-617-349-0205 Web site:
http://www.tktx.com/ Company News On-Call:
http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024